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Infectious complications of the hemodialysis access. Infectious in the United States [1]. In a subsequent report for the
complications of the vascular access are a major source of mor- years 1993 to 1995, the USRDS showed that infection ac-
bidity and mortality among hemodialysis (HD) patients. Nu- counted for 15.5% of adult end-stage renal disease (ESRD)merous reports implicate the vascular access in up to 48 to 73%
causes of death [2]. Mortality among the HD populationof all bacteremias in HD patients. The incidence of vascular
may even be of larger magnitude than what has tradition-access-related infection is highest when central venous dialysis
catheters are employed. Native arteriovenous fistulas carry the ally been appreciated from the USRDS. For example,
lowest risk of infection. Unfortunately, prosthetic arteriove- in a large cohort study of 532 patients starting HD and
nous grafts, which represent the most common type of HD ac- followed-up for 16 years, Mailloux et al showed thatcess in the United States, have been repeatedly shown to be a
death caused by infection accounted for 36% of all-causerisk factor for bacteremic and nonbacteremic infections. Silent
mortality [3]. In a retrospective autopsy-based analysisinfection in old nonfunctional clotted prosthetic arteriovenous
grafts has recently been recognized as a frequent cause of bac- of causes of mortality in 63 insulin-dependent diabetic
teremia and morbidity among HD patients. High proportions patients on HD, Zander et al found that infection ac-
of infections related to the vascular access are caused by staphy- counted for 20.6% of all deaths [4]. Perhaps the giganticlococcal organisms, which carry high rates of mortality, recur-
risk of death caused by infection in ESRD patients isrence, and metastatic complications. Management of vascular
best highlighted by Sarnak and Jaber, who comparedaccess-related infection has two aspects: The first relates to the
choice, duration, and mode of administration of antibiotic ther- annual mortality rates caused by sepsis in patients with
apy. Empiric antibiotic therapy, guided by demographic data ESRD with that in the general population [5]. In their
and severity of illness, should be employed when the causative comparative analysis, which relied on data from theorganisms are unknown. Prolonged administration of specific
USRDS for the years 1994 to 1996, they found 100- toparenteral antibiotics is crucial in decreasing complications of
300-fold higher risk of death caused by sepsis in ESRDinfection, especially in cases of staphylococcal bacteremia. The
second aspect relates to management of the vascular access. patients. Stratification for age, sex, gender, and the pres-
Efforts directed toward bacteriological cure should be concur- ence of diabetes did not significantly alter the magnitude
rent with efforts to preserve native venous access sites when- of such risk posed by the ESRD status.ever possible. Efforts to prevent vascular access-related infection
Of particular concern is that the HD vascular access hasshould focus on increasing placement of arteriovenous fistulas
emerged as a major risk factor for infection and bacter-and minimizing insertion of central venous dialysis catheters.
Careful inspection and monitoring of the vascular access is of emia [1, 6–20]. Numerous reports implicate the vascular
paramount importance in early detection of vascular access site- access in up to 48 to 73% of all bacteremias in the HD
related infections. Several new approaches aimed at preventing population (Table 1) [1, 8–10, 13, 18]. Furthermore, thecatheter and prosthetic graft-related infection are being explored.
majority of these bacteremias are caused by staphylococ-
cal organisms that are associated with high rates of mor-
tality (8 to 25%), recurrence (14.5 to 44%), and seriousInfectious complications continue to be among the
metastatic complications (14.5 to 44%) [7–20]. Amongforemost causes of morbidity and mortality in hemodial-
the most common complications are infectious endocar-ysis (HD) patients. The United States Renal Data System
ditis, septic arthritis, epidural abscess, septic pulmonary(USRDS) showed that for the years 1991 and 1992, infec-
emboli, and osteomyelitis [8–10, 14–17].tion accounted for 12% of all deaths among HD patients
The incidence of infection caused by the HD vascular
access is highest when it is a central venous catheter and
lowest when it is a native arteriovenous fistula [6, 7, 9, 13,Key words: vascular access, graft, catheter, infection, arteriovenous
fistula, prosthetic arteriovenous grafts, bacteremia. 14, 18–21]. Unfortunately, the prosthetic arteriovenous
graft composed of polytetrafluoroethylene (PTFE), whichReceived for publication July 25, 2000
has become an acceptable alternative to the native arte-and in revised form December 27, 2000
Accepted for publication January 31, 2001 riovenous fistula, when the latter is not surgically feasi-
ble, is very often plagued by infection [19, 22, 23]. In the 2001 by the International Society of Nephrology
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Table 1. Incidence of bacteremia in hemodialysis patients
Incidence of bacteremia Bacteremia due to % bacteremia due to
Source [reference] Country Year N per 100 patient-years vascular access gram-positive cocci
Dobkin et al. [13] USA 1978 N/A 15 73% 70%a
Kessler et al. [8] France 1993 1455 8.4 51% 69.80%
USRDS [1] USA 1996 USRDS 7.6 48% N/A
Marr et al. [9]b USA 1998 445 14.4 89% 100%
Kaplowitz et al. [18] USA 1988 71 8.4 27% 50%c
Hoen et al. [20] France 1998 988 11.2 N/A 68%
N denotes number of hemodialysis patients during the study period. N/A denotes data not available.
a Rate applies if bacteremia is vascular access-related
b A study on staphylococcal aureus bacteremia
c Percent of combined bacteremic and nonbacteremic infections related to vascular access
Table 2. Incidence of catheter-related bacteremia (CRB) in hemodialysis patients
Incidence of CRB % CRB due to
Source [reference] Country Year N per 1000 catheter-days gram-positive cocci
Moss et al. [28] USA 1990 131 0.7 N/A
Marr et al. [29] USA 1997 102 3.9 63%
Kairaitis and Gottlieb [21] Australia 1999 105 6.5 100%
Beathard [30] USA 1999 387 3.4 84.5%b
Saad [31] USA 1999 101 5.5 67.4%c
Cuevas et al (abstract)a Spain 1999 189 1.54 84%
Cuevas et al (abstract) Spain 1999 45 1 84%
N denotes number of patients with hemodialysis catheters; N/A denotes data not available.
a A study on temporary dialysis catheters
b Includes 9.8% of cultures due to mixed gram-positive and gram-negative infections
c Includes 12.8% cultures with mixed gram-positive and gram-negative infections
United States, the increasing use of dialysis catheters Earlier reports described lower infection rates with
[24] and the widespread placement of PTFE grafts [25] tunneled cuffed catheters as opposed to nontunneled
place HD patients at high risk of serious vascular access- double lumen catheters [27, 28]; however, this has not
related infections [1–22, 24]. been subjected to confirmation by large randomized tri-
als. In 1988, Schwab et al observed one CRB among 80
tunneled catheters with a median follow-up of eight
INFECTIONS RELATED TO weeks (3 weeks to 5.4 months) [27]. In 1990, Moss et al
DIALYSIS CATHETERS followed 168 tunneled dialysis catheters over a four-
Incidence year period (median catheter survival 18.5 months) and
reported 0.7 CRB per 1000 catheter-days [28]. MoreNumerous reports implicate tunneled (permcath) and
recent studies show less optimistic results. In Marr et al’snontunneled (temporary) dialysis catheters as important
recent prospective study of 102 tunneled catheters, thecauses of serious infections in HD patients (Table 2). In
incidence of CRB was found to be 3.9 episodes per 1000a large seven-year longitudinal study of 4005 incident
catheter-days [29]. Similar rates of tunneled CRB rang-ESRD patients in the case-mix study of the USRDS, Powe
ing between 3.4 and 5.5 per 1000 catheter-days wereet al found temporary vascular access as an independent
reported by other investigators (Table 2) [30, 31].risk factor for septicemia [7]. Hung et al studied 168 tem-
A recent prospective study involving 234 HD cathetersporary dialysis catheters for an average of 27.8 (9 to 73)
(45 of which were tunneled), presented by investigatorsdays. Catheter-related bacteremia (CRB) developed in
from Spain (abstract; Cuevas et al, J Am Soc Nephrol21.4% of cases. The cumulative probability of patients
10:204, 1999), found CRB to occur at similar rates amongremaining free from CRB was 75% by the end of four
tunneled and nontunneled catheters (1 per 1000 catheter-weeks and less than 50% near the end of the second
days with tunneled catheters vs. 1.54 per 1000 catheter-month [26]. A similar increase in the risk of developing
days with nontunneled catheters, P  0.98). However,CRB with longer duration of catheterization was also
the average time from catheter placement to infectionreported by Kairaitis and Gottlieb [21]. In their prospec-
was longer with tunneled catheters (66.2  84.5 days vs.tive study of 105 temporary dialysis catheters, CRB de-
veloped in 16% and exit site infections in 8% of cases. 20.6  29.4 days).
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Risk factors tion may on occasion be the first clue to CRB. HD
patients with suspicion of CRB must have blood culturesSeveral studies have attempted to define the risk fac-
done immediately and should be promptly initiated ontors involved in CRB. Both the site of insertion and the
empiric antimicrobial therapy.duration of use influence the rate of infection. Femoral
Management of CRB in the HD patient has two as-catheters are more susceptible to infections than thoracic
pects. The first relates to antimicrobial therapy. Initialcatheters [11]. This may relate to accumulation of sweat
empiric antibiotic therapy should take into considerationand moisture around the exit site. Kairaitis and Gottlieb
the frequency of the bacterial isolates in such settings.found temporary HD catheters placed in the internal
Staphylococcal species have repeatedly been demon-jugular vein to be associated with higher infection rates
strated to be the most prevalent (60 to 100%) bacterialthan those placed in the subclavian vein [21]. However,
isolates in HD patients with CRB [12–14, 20, 21, 24, 26,these results should not justify routine use of subclavian
30]. The prevalence of S. aureus and coagulase negativeveins for HD catheters for two reasons. First, these find-
staphylococci bacteremia is similar in most series [20,ings may not apply to tunneled catheters. Second, the
24, 26, 30, 31, 37]. Enterococci have been found in 11 tosubclavian location carries the highest rate of catheter
19% of CRB [26, 30, 31]. Gram-negative rods are re-associated central venous stenosis [24]. The duration of
ported in up to 33% of cases [30, 31]. In some patients,catheter use is also important as the risk of infection
both gram-positive and gram-negative organisms haveincreases linearly with time [21, 26].
been isolated from the blood stream, indicating mixedAmong local factors, poor personal hygiene, use of oc-
bacteremia [30, 31]. These data mandate that empiricclusive transparent dressing, and accumulation of mois-
antibiotic therapy should target both gram-positive andture around the exit site have been described as risk
gram-negative organisms. Empiric therapy that ignoresfactors for CRB [18, 24]. Nasal and skin colonization
the possibility of gram-negative rods as mediators ofwith Staphylococcus aureus, as well as bacterial coloniza-
CRB places a considerable number of patients at unwar-tion of HD catheters, has been reported as a risk factor
ranted risk and should not be a consideration. Specificfor systemic infection [12, 32–35]. Systemic factors such
antimicrobial therapy should replace empiric therapy as
as immunosuppression [20], diabetes mellitus [21, 28],
soon as the identity of the bacterial isolate is determined.
low albumin [6, 7, 36], and high ferritin [24] have been The other aspect of management is related to removal
found to be associated with increased risk of CRB. of the HD catheter, which is the source of the bacteremia
In addition to bacteremia, catheter-related exit site (Fig. 1). While this approach is scientifically the most
infections are common complications of HD catheter correct, it poses certain practical problems, especially
use (8 to 21% of cases) and are important causes of in HD patients whose vascular access sites have been
catheter loss [21, 28, 30]. With tunneled catheters, infec- exhausted. In an attempt to preserve venotomy sites,
tions external to the cuff are classified as exit site infec- Beathard prospectively evaluated a more conservative
tions, whereas infections that extend in the tunnel proxi- approach in a series of 114 patients with CRB [22, 30].
mal to the cuff are labeled as tunnel infections [24, 30]. While all of his patients were appropriately treated with
Tunnel infections are more serious because of their fre- antibiotics, catheter management depended on the clini-
quent association with bacteremia [24, 30]. Several re- cal picture. Patients with severe clinical symptoms had
ports have identified poor patient hygiene and diabetes catheter removal with delayed replacement after defer-
mellitus as risk factors for exit-site infections [21, 24, 28]. vescence (86.5% cure rate). Patients with minimal symp-
toms but with tunnel or exit site infection had a catheter
Diagnosis and management exchange over a guide wire with creation of new tunnel
Catheter-related bacteremia may have various clinical (75% cure rate). Patients with minimal symptoms and a
presentations. The acute onset of fever and chills in a normal-appearing tunnel and exit site had a catheter
patient with a HD catheter and no localizing signs is exchange over a guide wire within 48 hours of antibiotic
easily recognized and is generally considered to be a initiation (87.8% cure rate). Cure rates were defined as
CRB until proven otherwise. Such an explosive presenta- a 45-day, symptom-free interval after antibiotic therapy
tion is often observed during the hemodialytic proce- was complete [30]. In keeping with these results, Tanri-
dure, but could occur at any time during the interdialytic over et al conducted a retrospective study in which they
period. Less acute presentations of CRB are also fre- compared the outcomes of two treatment strategies for
quent, especially in the older population and the immu- CRB in HD patients: catheter exchange over a guide
nocompromised. These may include any of the following: wire (31 catheters) versus catheter removal with delayed
the insidious onset of low-grade fever, hypothermia, leth- replacement (38 catheters). The infection-free survival
argy, confusion, hypotension, hypoglycemia, or diabetic was similar with both strategies that included three
ketoacidosis. Such insidious presentations may cause de- weeks of systemic antibiotic therapy [36].
Treatment of CRB with antibiotics while the catheterlay in the diagnosis, and a metastatic infectious complica-
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Fig. 1. Management of infection in hemodialysis (HD) patients whose vascular access is a tunneled central venous dialysis catheter.
remains in place has been advocated by some authors; Newer strategies to prevent catheter-related infection
however, Marr et al observed a failure rate of 68% with A gentamycin/sodium citrate mixture has been used
this approach [29]. Most authorities do not consider this with preliminary success as an antibiotic-lock technique
approach a treatment option and advocate catheter re- for salvage and prevention of catheter-related infections.
moval or exchange [24, 29–31]. Bacteria adherent to a Sodemann et al described near elimination of catheter
related infections with this mixture when installed in thebiofilm on the inner or outer surfaces of the catheter are
HD catheter lumen at the end of dialysis instead of heparinunlikely to be eradicated by antibiotic administration
(abstract; Sodemann et al, J Am Soc Nephrol 8:173,and are suspected to be the cause of recurrent bacteremia
1997). Similar favorable results were observed by Ashwhen the catheter is not exchanged [37].
et al, who described a decrease in the incidence of CRBExit site infections are common and are recognized
from 4.5 to 1.6 episodes per 100 patient-months followingby redness, exudation, and crusting. Unless associated
the use of a catheter lock solution (abstract; Ash et al,with bacteremia or tunnel infection, exit site infections
J Am Soc Nephrol 10:272, 1999). The latter consisted ofshould be treated conservatively [24, 28, 30]. Topical
10 or 20% sodium citrate mixed with gentamycin at 2.3
antiseptics and local application of antimicrobials may mg/mL. In the same meeting, Ash et al reported that
be sufficient in milder cases. Systemic antibiotics should concentrated sodium citrate (47%), without gentamycin,
be used in cases that fail to respond to topical therapy. was also successful in preventing catheter-related infec-
Catheter removal may become necessary if the previously tion when used as a catheter lock solution by virtue of
mentioned measures fail to eradicate the exit site infec- its bactericidal and sporicidal activity in vitro. However,
tion. Tunnel infection is best treated by catheter removal the Food and Drug Administration (FDA) has recently
cautioned against the use of 47% sodium citrate (but notand the replacement at a new venotomy site [24, 30].
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4% solution) as a dialysis catheter lock solution for fear tional twin catheter system. While this system is not totally
free of the mechanical complications that affect dialysisof adverse events (for example, hypocalcemia) should
concentrated citrate accidentally enter the blood stream. catheters, preliminary reports describe lower rates of
bacteremia (0 to 3 per 1000 catheter days) [44–46].An antibiotic heparin lock may prove to be useful in
central venous catheters. Preliminary studies by Vercaigne
et al tested the in vitro stability of antibiotic heparin
INFECTIONS OF THE ARTERIOVENOUS ACCESS
combinations [38]. While ciprofloxacin produced imme-
Arteriovenous fistula versus graftdiate precipitation with heparin, cefazolin, vancomycin,
and ceftazidime at 10 mg/mL and gentamycin at 5 mg/mL The arteriovenous HD access includes the native arte-
riovenous fistula and the synthetic arteriovenous graft.were successfully incubated with heparin (5000 U/mL)
for 72 hours in the central venous catheter lumen. Despite In 1995, a large U.S. national survey, conducted by the
Centers of Disease Control (CDC) and involving 224,954progressive reductions in free antibiotic levels, largely
caused by adherence to the inner luminal surface of the HD patients, showed that only 22% of patients were dia-
lyzed through a native arteriovenous fistula [25]. This iscatheter, sufficient bactericidal antibiotic concentrations
persisted at 72 hours [38]. These encouraging results pro- unfortunate because the probability of dialysis access-
related infection is considerably less for patients withvide the basis for further investigation of the usefulness
of the antibiotic heparin catheter lock in preventing CRB. native arteriovenous fistula than for those with synthetic
grafts [6, 9, 14, 19, 47]. Postoperative wound infectionIn an attempt to minimize central venous catheter-
related infection in intensive care units, Maki et al stud- as well as poor aseptic technique at dialysis may cause
infection of the fistula. In most instances, such infectionsied the usefulness of a subcutaneous silver-impregnated
attachable cuff in a prospective randomized multicenter are successfully managed by systemic antibiotics and con-
servative surgery, but can lead to loss of the fistula [47].trial, which involved 234 catheters (not for dialysis) [39].
The results demonstrated nearly fourfold less bacteremia In the United States, the majority of current arteriove-
nous grafts are of PTFE material. PTFE arteriovenouswith this cuffed catheter (1.0 vs. 3.7%). In addition, cath-
eters with the cuff were threefold less likely to be colo- grafts have gained widespread popularity because of ease
of placement at sites where it is surgically unfeasible tonized on removal (9.1 vs. 28.9%). Similar results were
obtained with central venous catheters impregnated with create a native arteriovenous fistula. This surgical success
has created two untoward consequences: high rates of arte-chlorhexidine and silver sulfadiazine [40].
In keeping with the same concept, catheters impreg- riovenous access thrombosis and infection [22, 23, 48–50].
In the United States, the vast majority of arteriovenousnated with minocycline and rifampin were developed.
In vitro and animal studies suggest that these catheters access-related infections are associated with PTFE grafts.
resist infection more effectively than catheters impreg-
Incidence and risk factorsnated with chlorhexidine and silver sulfadiazine [41, 42].
Darouiche et al recently published the results of a pro- The risk of PTFE infection starts at the time of surgical
placement. Zibari et al reported an initial 30-day graftspective, randomized clinical trial with 865 central venous
catheters (not for dialysis) and showed that catheters im- infection rate of 6% in 208 patients undergoing PTFE
placement [49]. The femoral location (thigh graft) of PTFEpregnated with minocycline and rifampin are associated
with lower rates of colonization (7.9 vs. 22.8%) and CRB grafts is associated with higher postoperative wound in-
fection rates caused by sweat and moisture accumulation(0.3 vs. 3.4%) in comparison with catheters impregnated
with chlorhexidine and silver sulfadiazine [43]. Such in between the overlying skin folds [47]. This is of particu-
lar concern in obese patients, diabetics, and those withcatheters are not yet commercially available to the HD
community; however, an initial trial with minocycline/ poor hygiene. While the incidence of postoperative PTFE
infection can be reduced with prophylactic antimicrobialrifampin-impregnated HD catheters is being conducted
in the University of Texas in Houston (personal commu- therapy [49], a persistent risk of infection continues to
haunt the PTFE graft through out its lifetime.nication with Dr. Darouiche).
To eliminate the external location of dialysis catheters, A considerable risk of PTFE graft infection is posed by
the need for repetitive cannulation of the graft for dialytica totally implantable port-system has been developed as
a dialysis access (Biolink Corp., Middleboro, MA, USA). purposes [50]. Difficulty in cannulation of the PTFE graft,
perigraft hematoma formation, prolonged postdialysisIt consists of a subcutaneously implanted metallic cham-
ber connected to permanent silicone twin catheters. The bleeding from the graft, and a break in the sterile tech-
nique further increase the likelihood of PTFE graft infec-chamber is implanted subcutaneously in the chest area
below the clavicle, and the twin catheters end in the right tion at needle puncture sites. Bonomo et al found surgical
manipulation to be a risk factor for graft infection [19].atrium (Biolink Corp.). This system is referred to as Dia-
lock and is accessed percutaneously at each dialysis session In their study of 51 graft infections in 31 patients, the
risk of graft infection increased linearly with the numberwith special needle cannulas that convert it to a conven-
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of surgical revisions. Curi et al studied the outcome of required to diagnose silent infection in functional PTFE
grafts. In such instances, indium scanning of prostheticarteriovenous access in 42 HIV-positive patients and
found HIV-positive status to be a risk factor for PTFE grafts is an extremely helpful tool in diagnosing clinically
silent infection, as discussed later in this article.graft infection but not for native arteriovenous fistula
[51]. PTFE graft infection occurred in 30% of their HIV
Newer strategies to prevent arteriovenouspositive versus 7% of their HIV negative HD patients.
access-related infectionPoor patient hygiene has been recognized as a risk factor
for graft infection [18], whereas diabetes mellitus [7], A recent development in the area of the HD access
is the availability of cryopreserved human femoral veinshypoalbuminemia [7, 35], advanced age [7, 18], and high
serum ferritin [8] have been recognized as general risk for use as arteriovenous access grafts (CryoLife, Inc.,
Kennesaw, GA, USA). These cryoveins have the abilityfactors for infection in HD patients.
Infection of PTFE graft material may also develop as to revascularize, thus allowing the patient to fight and
resist infection. Since 1996, over 500 cryopreserved su-a result of a transient bacteremia caused by an infection
at a distant site [19]. Central venous catheters are notori- perficial femoral vein allografts have been implanted for
HD access. In many of these cases, these vein allograftsous for causing bacteremia and should be regarded as a
risk factor for bacterial infection of the PTFE graft. Once were placed in the setting of systemic or local infection.
Initial experience by Matsuura et al shows a remarkableinfected, the PTFE graft may in turn act as a source of
bacteremia at a subsequent date when the original source absence of cryovein-related infection (abstract; Matsu-
ura et al, 24th Annual Meeting of the Peripheral Vascularof infection had been eliminated and forgotten.
Surgery Society, 1999). The rarity of cryovein-related
Diagnosis and management infection in these preliminary reports is promising for
patients with history of repeated PTFE graft infectionsInfection of the arteriovenous graft is often recognized
clinically. Signs and symptoms of local infection may and exhaustion of dialysis arteriovenous access sites. In
these patients, cryovein arteriovenous grafts may beinclude any of the following: pain, irritation, tenderness,
redness, warmth, diffuse or localized swelling, serous or placed at new sites, but their placement at old graft sites
seems possible despite the presence of intercurrent PTFEpurulent discharge, and skin breakdown. The lack of such
signs and symptoms does not exclude the possibility of graft infection (personal communication with Dr. Matsu-
ura). In such clinical scenarios, Matsuura et al advocateclinically silent graft infection, especially in cases of unex-
plained sepsis, leukocytosis, or fever of unknown origin. one operation in which cryovein graft is created at the
same site while the infected PTFE graft is being removed.Management of PTFE graft infection has to strike a
balance between an attempt for bacteriological cure and This leads to salvage of angioaccess sites that would have
otherwise been abandoned. In keeping with the samepreservation of venous access sites (Fig. 2). In doing so,
it is extremely important to recognize signs and symp- concept, lower rates of arteriovenous access-related in-
fection were also observed with the use of denaturedtoms of graft-related infection very early when it may be
amenable to therapy with systemic antibiotics and local homologous vein grafts, as opposed to PTFE grafts, in
a prospective randomized multicenter trial [54].measures. Many local infections of the arteriovenous graft
site can be cured with early aggressive medical therapy
without resorting to graft excision [52]. However, abscess
INFECTIONS OF OLD CLOTTED
formation in the immediate proximity to the graft, puru-
ARTERIOVENOUS GRAFTS
lent drainage from infection that dissects onto the graft
Incidence and diagnosismaterial, and infected aneurysmal dilations of the graft
require surgical excision of the graft or a segment of it. The risk of PTFE graft infection in the HD patient
does not end when the graft is no longer in use. SuchThis is especially true when the source of bacteremia
is an obvious PTFE graft infection. It is our personal grafts are typically nonfunctioning with a thrombosed
lumen. It is common practice to leave these clotted graftsexperience that conservative excision of infected seg-
ments of PTFE grafts is associated with high rates of in place, and thus, many HD patients have one or more
old clotted grafts in their extremities. Even though theserecurrent infection necessitating total graft excision.
Therefore, careful observation and follow-up are neces- old clotted grafts tend to be considered innocuous by
most health care practitioners, it has recently been recog-sary when conservative surgical measures are employed.
When bacteremia occurs in the absence of clinical nized that they may harbor occult bacterial infection that
can lead to serious infectious complications [55–57].signs of graft infection, silent arteriovenous graft infec-
tion may go undetected. Such episodes may be more It is difficult to diagnose infection in old clotted grafts
largely because of the fact that such infections tend tocommon than what is generally appreciated and may
explain the high rates of recurrent bacteremia in patients be silent. Clinical recognition of PTFE-related infection
is easy when there is tenderness, erythema, warmth, in-with synthetic grafts [9, 53]. A high index of suspicion is
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Fig. 2. Management of infection in hemodialysis (HD) patients whose vascular access is a synthetic arteriovenous (AV) graft.
duration, or local drainage around the graft. In patent Blood cultures were positive for bacterial pathogens
grafts, these localizing signs of infection are often noted in 15 of the 20 febrile patients, indicating that serious
at the sites of previous graft punctures or surgical manip- illness was present. In contrast, all of the asymptomatic
ulation. In old clotted grafts, these signs are frequently control subjects had negative blood cultures. Indium up-
absent. Thus, the diagnosis of clinically silent graft infec- take in or around the clotted grafts was present on scan-
tion requires a high index of suspicion and is frequently ning in all 20 patients and in 15 of the control subjects.
missed [55–57]. The importance of the indium scan findings was verified
To evaluate the prevalence and clinical relevance of when purulent infected material was recovered from
silent infection in clotted grafts, we studied a series of 20 graft material in all 20 patients and in 13 of 15 indium
HD patients with old clotted PTFE grafts who presented scan-positive control subjects. The pathogens recovered
with fever (15 patients) or fever and clinical signs of
from blood culture were identical to those cultured fromsepsis (5 patients) in whom the source of infection was
the graft material in all patients, strongly indicating anot immediately localized to any organ system [55]. A
causal relationship. By far the most frequent pathogenscomparison was made with 21 asymptomatic HD patients
recovered from the graft material were S. aureus, fol-with clotted PTFE grafts who served as control subjects.
lowed by Staphylococcus epidermidis. Other less frequentBoth febrile patients and control subjects were evaluated
pathogens were Escherichia coli, Serratia marcescens,with indium scans and then subjected to surgical removal
and Streptococcus pneumonia.of the graft. Bacterial cultures of the recovered surgical
Indium scan is a well-established and accepted methodmaterial and blood were done simultaneously in all study
participants. for localization of infection in general [58, 59]. This tech-
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Fig. 3. Indium 111-labeled leukocyte scan
showing diffuse and intense tracer uptake in
a prosthetic upper arm arteriovenous graft in-
dicating high likelihood of infection. The scan
also shows mild tracer uptake in a prosthetic
forearm arteriovenous graft also suspicious
for infection. These grafts were old, clotted,
and nonfunctional accesses in a 63-year-old
woman on HD suffering from hypoalbumi-
nemia and anemia resistant to erythropoietin.
Surgical excision of these grafts uncovered pu-
rulent material, from which S. aureus organ-
isms were recovered. Following graft excision
and treatment with antimicrobials, serum al-
bumin increased and erythropoietin resistance
resolved. Note that tracer uptake by bone, as
seen on the scan, is not of pathologic signifi-
cance.
nique requires administration of autologous indium-111– tients. In support of the latter concern is a recent report
by Fishbane et al, who found high rates of occult bacteriallabeled leukocytes and subsequent (24 h later) total body
scanning with a gamma camera (Fig. 3). It has been infection in nonfunctioning arteriovenous grafts among
their HD patients with refractory anemia and low serumshown to be useful in vascular graft infection, with overall
satisfactory sensitivity and specificity [60, 61]. A variety albumin (abstract; Fishbane et al, J Am Soc Nephrol,
10:1402, 1999). Excision of the graft led to a decline inof lesions other than foci of bacterial infection can pro-
duce positive results, but an intense focal uptake is un- serum C-reactive protein (CRP) levels and total serum
ferritin, along with a rise in serum albumin and improvedcommon in lesions other than abscesses and hematomas.
In our experience, the indium scan demonstrated a sensi- responsiveness to erythropoietin. Preliminary data from
our HD patients also show improvement of serum albu-tivity of 100% and a specificity of 75% for graft infection
[55]. We therefore advocate indium scanning as a diag- min following excision of PTFE grafts harboring occult
infection (unpublished observations). While the link be-nostic tool to investigate the possibility of graft infection
when such suspicion exits in the absence of clinically tween occult PTFE graft infection and chronic inflam-
mation has not been adequately studied, it is worthy toobvious signs.
mention that serum CRP levels, which are markers of
Management and risk factors chronic inflammation, are significantly higher in asymp-
tomatic HD patients in comparison with those on perito-The natural history of silent PTFE infection has not
been studied prospectively, but spontaneous resolution neal dialysis [62, 63].
Infected old clotted PTFE grafts should be surgicallyis unlikely. We also doubt reliable resolution of infection
with antimicrobial therapy since it involves foreign mate- excised without any delay, and systemic antibiotics
should be administered. It is tempting to conclude thatrial. Two concerns emerge. The first is obvious and re-
lates to acute dissemination of bacterial infection into old PTFE grafts should be routinely excised because
they frequently are sites of infection [55–57]. At present,the blood stream or other organ systems. The second
concern is less obvious but equally grave; it evokes the there are no prospective data to address this question
appropriately. However, the common practice of rou-possibility that silent graft infection may be a contributor
to the “chronic inflammatory state” that afflicts HD pa- tinely leaving clotted nonfunctioning grafts in place pre-
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Table 3. Risk factors for arteriovenous graft infection Emergence of vancomycin resistant enterococci
Diabetes mellitus With the emergence of vancomycin-resistant entero-
Immuno-incompetency cocci (VRE) and the recognition of HD and peritonealRenal transplantation
dialysis as independent risk factors for VRE bacteremiaIndwelling central venous catheter
History of bacteremia [65–68], the empiric use of vancomycin in the febrile
Previous major infection in any organ system patient on HD has recently been challenged by severalPrevious arteriovenous graft-related infection
authorities [69, 70]. Among these are the CDC, whichPrevious arteriovenous graft-related surgery
Fever of unknown origin published guidelines for the prudent use of vancomycin
in an attempt to prevent the spread of vancomycin resis-
tance [70]. In accordance with these guidelines, empiric
treatment with vancomycin is appropriate in patients with
disposes many HD patients to the risk of developing -lactam allergy or in instances when serious infections
serious infectious complications [57]. If we are not in a with -lactam-resistant gram-positive bacteria (MRSA,
position to advocate removal of all nonfunctioning PTFE S. epidermidis) are likely. In a given dialysis facility, the
grafts, then we need to identify a subgroup of patients likelihood of such infections can be determined by know-
ing the percentage of MRSA isolates and the percentagewho are at added risk of PTFE infection. It is our per-
of serious infections caused by S. epidermidis. Continu-sonal experience that the following factors identify pa-
ing treatment, however, depends on culture results. Iftients at such risk: diabetes mellitus, immunoincompe-
the patient is allergic to-lactam antibiotics or if-lactam-tency, renal transplantation, indwelling central venous
resistant bacteria are isolated, vancomycin is appropriate.catheter, previous bacteremia, previous infection in any
organ system, previous PTFE graft-related infection, and
Alternatives to vancomycinfever of unknown origin (Table 3) [57]. In these patients,
The use of parenteral cefazolin, as an alternative toevidence of infection in their old clotted PTFE grafts
vancomycin, either singly or in combination with genta-should be actively investigated and managed.
mycin, has recently been explored in HD patients. In a
retrospective review of blood and wound culture results
from a 217-patient, non–hospital-based outpatient HDGENERAL CONSIDERATIONS IN
center, Fogel et al found cefazolin to be equivalent toANTIMICROBIAL THERAPY
vancomycin for empiric treatment of clinically significantEmpiric antimicrobial therapy
infections in a population with a low rate of MRSA
Fever in the HD patient may have various etiologies, [71]. In the same report, a prospective pharmacokinetic
and antimicrobial therapy should be tailored accordingly analysis in anuric HD patients demonstrated safe and
[64]. When the source of fever is suspected to be due to effective peak and trough cefazolin levels with 1 g postdi-
the HD access (catheter or graft), antimicrobial therapy alysis dosing. Similarly, Marx et al were successful in
must reliably cover gram-positive species (including using empiric postdialysis cefazolin (20 mg/kg) to treat
methicillin-sensitive S. aureus), since these organisms ac- 15 consecutive HD patients suffering from various infec-
count for about two thirds of HD access-related bacter- tions [72]. Collectively, these data support two conclu-
emias [8–10, 12–18, 20, 21, 24, 26–31, 55–57]. Enterococci sions. First, for infections with documented sensitivity to
and gram-negative organisms account for the majority cefazolin in anuric HD patients, intravenous postdialysis
of the remaining bacteremias, and antimicrobial therapy dosing of cefazolin is both safe and effective, and second,
should target these organisms as well [18, 25, 30, 31, 55–57]. empiric treatment of non–life-threatening infections with
Based on the previously mentioned data, it has become cefazolin alone or in combination with gentamycin may
a common practice to treat the febrile HD patient empiri- be appropriate in HD patients in a facility with low
cally with a combination of parenteral vancomycin plus MRSA infection rates, pending culture results (Fig. 4).
gentamycin. The popularity of this combination is due
Complications of bacteremiato two reasons: (1) It provides broad spectrum antimi-
crobial coverage, which includes methicillin-resistant S. Infectious complications of bacteremia are a frequent
aureus (MRSA) and enterococci, and (2) based on the occurrence in HD patients. Death, recurrence of bacter-
pharmacokinetics of vancomycin and gentamycin, it emia, endocarditis, epidural abscess, purulent pericardi-
allows convenient in-center dosing, once or three times tis, septic arthritis, septic pulmonary emboli, liver ab-
weekly, respectively. The empiric use of this combination scess, and endophthalmia have all been reported as
(or vancomycin plus a third generation cephalosporin) complications of bacteremia [8, 14–16]. By far, the lead-
is medically justified in HD patients when bacteremia is ing bacterial isolate in HD patients with metastatic com-
plications is S. aureus [8, 14–16]. Infectious endocarditissuspected (Fig. 4).
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Fig. 4. Initial management and empiric use of antimicrobials in hemodialysis (HD) patients with fever. MRSA denotes methicillin-resistant S. aureus.
is the most dreaded of these complications. Robinson et or death if the diagnosis is delayed. Obrador and Leven-
son summarized data on 12 HD patients with spinal epi-al reported a 30% mortality rate in a series of 20 HD
patients with infectious endocarditis [14]. In addition, dural abscess and found back pain and radicular pain to
be the most common signs at presentation [15]. S. aureus25% required heart valve replacement. Transthoracic
echocardiography is likely to miss the majority of infec- was implicated in all of these cases. Magnetic resonance
imaging with gadolinium or myelography is the besttious endocarditis cases; therefore, establishing the diag-
nosis requires a high index of suspicion coupled with available tools for establishing the diagnosis of epidural
abscess. Early recognition and treatment with antibioticstransesophageal echocardiography [14]. Another serious
complication is the occurrence of spinal epidural abscess, and decompressive laminectomy is associated with better
outcome.which can evolve to severe permanent neurologic deficit
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Duration of antibiotic therapy eral steps should be carried out at various levels of care
to minimize the global impact of vascular access-relatedWhen bacteremia is documented by positive blood
infection.cultures, the duration of antimicrobial treatment should
The first step in minimizing the frequency of vascularbe sufficiently prolonged so as to minimize recurrence of
access-related infection should be a serious attempt tobacteremia and prevent the occurrence of the previously
mentioned infectious complications. These complica- increase the percentage of HD patients whose vascular
tions are more common with short (two weeks or less) access is an arteriovenous fistula. These accesses are
courses of antimicrobial therapy, and several authorities associated with the least risk of infectious complications.
advocate at least four weeks of adequate antibiotic ther- The second step is recognition of risk factors for HD
apy for S. aureus bacteremia [73]. For all other organ- vascular access infection. Some of these factors, such as
isms, a minimum of three weeks of adequate antimicro- the presence of diabetes mellitus, immunosuppression,
bial therapy is advocated [30]. and low serum albumin, may not be amenable to modifi-
cation. However, other risk factors such as nasal S. aureusNasal mupirocin
carrier status, poor personal hygiene, and improper can-
Nasal carriage of S. aureus is a risk factor for the
nulation techniques at dialysis are important to recognizedevelopment of S. aureus bacteremia in HD patients
and modify. Prophylactic antibiotics are useful in certain[33, 34]. Nasal mupirocin ointment has been successfully
situations such as patients undergoing surgical proce-used to eradicate nasal carriage of S. aureus [33–35].
dures on their PTFE grafts.Boelaert et al found fourfold reduction in the incidence
The third step is early recognition and treatment ofof S. aureus bacteremia with intranasal mupirocin during
vascular access-related infection. Careful monitoring of167.7 patient years of HD [33]. Nasal mupirocin did
the vascular access is essential, and prompt treatmentnot lead to the development of bacterial resistance or
of suspected infection may be life saving. In many in-overgrowth of other microorganisms [33, 34]. Hence,
chemoprophylaxis with intranasal mupirocin in HD pa- stances, recognition of infection requires a high index of
tients who are nasal carriers of S. aureus seems cost- suspicion. For example, occult infection in old clotted
effective [33]. arteriovenous grafts may not be associated with overt
signs of local infection. In such instances, a leukocyte-
labeled indium scan is likely to demonstrate evidence ofCOST CONSIDERATIONS
graft infection. Empiric antimicrobial therapy of vascularIt is well known that morbidity of the dialysis vascular
access-related infection should target both gram-positiveaccess is one of the most important causes of hospitaliza-
as well as gram-negative bacteria. Specific antimicrobialtion in the U.S. ESRD population [74]. In 1986, approxi-
therapy should replace empiric therapy whenever themately 17% of all-cause hospitalization among the U.S.
identity of the bacterial isolates mediating infection isESRD population was vascular access-related, and the
known. Prolonged systemic antimicrobial therapy is es-number of vascular access-related hospital days was ap-
sential to prevent recurrence of infection as well as seri-proximately 40,000. By 1991, over 20% of all-cause hos-
ous metastatic infectious complications. In addition topitalization was vascular access related, representing
antimicrobial therapy, proper management of vascular70,000 hospital days. In 1996, Feldman, Kobrin, Was-
access-related infection requires a plan of managementserstein estimated the total annual cost of vascular access
morbidity to be approximately 10% of the total U.S. of the vascular access itself, which in turns depends on the
ESRD budget and projected that this cost will likely clinical scenario. For example, bacteremia in association
exceed $1 billion in the ensuing years [74]. Unfortu- with a HD catheter mandates removal of the catheter,
nately, the percentage of this total annual cost that is due and purulent drainage in proximity to PTFE graft mate-
infection is not known, but we believe it is substantial. rial requires a minimum of segmental graft excision.
The fourth step relates to exploring novel approaches
directed at decreasing the risk of vascular access-relatedCONCLUDING REMARKS
infection. The use of antibiotic-lock techniques in theThe vascular access imposes a serious risk of life-
HD catheter lumen during the interdialytic period hasthreatening infections that lead to significant morbidity
been initially successful in decreasing catheter-associatedand mortality among the HD population. While central
infections. The use of HD catheters impregnated withvenous catheters provide immediate vascular access,
antimicrobial agents is being investigated in HD patients.they carry the highest risk of bacteremia. Arteriovenous
Preliminary experience with human cryoveins suggestsPTFE grafts, the most common type of arteriovenous
a significant reduction in arteriovenous access-relatedaccess for HD in the United States, are also frequent
causes of bacteremic and nonbacteremic infections. Sev- infections.
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